Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

Abstract

Background Since “Helicobacter pylori (H. pylori) infection” was set as the indication in the Japanese Society for Helicobacter Research (JSHR) Guidelines 2009, eradication treatment for H. pylori gastritis is covered under insurance since 2013 in Japan, and the number of H. pylori eradication has rapidly increased. Under such circumstances, JSHR has made the third revision to the “Guidelines for diagnosis and treatment of H. pylori infection” for the first time in 7 years. Methods The Guideline Committee held 10 meetings. Articles published between the establishment of the 2009 Guidelines and March 2016 were reviewed and classified according to the evidence level; the statements were revised on the basis of this review. After inviting public comments, the revised statements were finalized using the Delphi method. Results There was no change in the basic policy that H. pylori infectious disease is an indication for eradication. Other diseases presumed to be associated with H. pylori infection were added as indications. Serum pepsinogen level, endoscopic examination, and X‐ray examination were added to the diagnostic methods. The effects of 1‐week triple therapy consisting of potassium‐competitive acid blocker (P‐CAB), amoxicillin, and clarithromycin have improved, and high eradication rates can also be expected with proton pump inhibitors (PPI) or P‐CAB combined with amoxicillin and metronidazole. If the susceptibility test is not performed, the triple PPI or P‐CAB/amoxicillin/metronidazole therapy should be chosen, because the PPI/amoxicillin/metronidazole combination demonstrated a significantly higher eradication rate than PPI/amoxicillin/clarithromycin. In the proposal for gastric cancer prevention, we divided gastric cancer prevention measures by age from adolescent to elderly, who are at an increased gastric cancer risk, and presented measures for gastric cancer prevention primarily based on H. pylori eradication. Conclusion We expect the revised guidelines to facilitate appropriate interventions for patients with H. pylori infection and accomplish its eradication and prevention of gastric cancer.

Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study

“…In all patients, the fecal antigen test was used to establish the diagnosis of H. pylori infection as well as to prove its eradication. This test was done one month after antibiotic treatment completion and 2 weeks after stopping therapy with pantoprazole (29). This test was also repeated at the end of therapy to identify any reinfection.…”

Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability

“…46 For this reason, guidelines suggest that all patients with active H. pylori infection should be offered treatment. 16,41,42 Given the enormous morbidity and mortality attributable to H. pylori infection in Myanmar, a national eradication programme is both desirable, but also importantly, economically feasible. The country has made enormous progress against malaria, tuberculosis and HIV/AIDS, diseases that are, arguably, far more difficult to treat that H. pylori.…”

Hellenic consensus on Helicobacter pylori infection

“…However, according to the Kyoto Consensus, H. pylori eradication cannot "reset the clock" to zero (i.e., no risk) but can stop the progression of risk and stabilize or decrease the subsequent risk [12]. Moreover, until now, Asian guidelines recommend H. pylori eradication in patients with AG and IM [203][204][205]. According to the European Union guidelines, the European Maastricht V Consensus, H. pylori eradication results in significant improvement in gastritis and AG but not in IM [3].…”